MedTrace Logo

The Comparative Effectiveness Dementia & Alzheimer's Registry

NCT03687710 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 452

Last updated 2026-03-30

No results posted yet for this study

Summary

To evaluate the effectiveness of using clinical precision medicine to develop lifecourse interventions for Alzheimer's disease (AD) prevention and treatment. Anthropometrics, blood biomarkers (including genetics), and cognition will measured longitudinally to assess the comparative effectiveness of clinical care.

Conditions

Interventions

BEHAVIORAL

Multidomain precision medicine intervention

Participants will receive individualized evidence-based multidomain interventions (education, pharmacologic, non-pharmacologic) in the setting of routine outpatient clinical care.

Sponsors & Collaborators

  • Weill Medical College of Cornell University

    lead OTHER

Principal Investigators

  • Schantel Williams, MPH, RN · Program Director of Alzheimer's Prevention Program

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-16
Primary Completion
2028-06-30
Completion
2028-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03687710 on ClinicalTrials.gov